Erasca, Inc.

Background

Company Name	Erasca, Inc.
Stock Symbol	ERAS
Class Period	January 14, 2025 to April 26, 2026
Lead Plaintiff Motion Deadline	August 10, 2026

Submit Your Information

If you suffered a loss on your Erasca, Inc. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. Please note that submission of this form does not by itself form an attorney-client relationship nor does filling out this form mean you have joined any lawsuit.

First Name*

Middle Initial

Last Name*

Email*

Phone*

If representing a Corporation, Trust, Partnership or other entity, Name of Entity

If representing an Entity, Position at Entity

Mailing Address

City

State/Province

ZIP/Postal Code

Country

Are you a current or former employee of the company?

Did you purchase any shares before January 14, 2025?

Shares Purchased

Number of Shares	Buy Date	Price Per Share	Add
Purchased quantity	Purchased month Purchased day Purchased year

Shares Sold

Number of Shares	Sell Date	Price Per Share	Add
	Sold month Sold day Sold year

Additional Comments

Background

On April 27, 2026, before market hours, Erasca disclosed that it had received a letter from legal counsel for Revolution Medicines, Inc. (“RevMed”) alleging that Erasca’s drug candidate, ERAS-0015, infringes a RevMed patent and is connected to alleged trade secret misappropriation. RevMed also claimed that Erasca had “improperly compared preclinical data of ERAS-0015 and RMC-6236 in public disclosures” and demanded Erasca cease making “deceptive and untrue comparative statements comparing ERAS-0015 and RMC-6236.”

On this news, Erasca’s stock price fell $2.34, or 10.9%, to close at $19.15 per share on April 27, 2026, thereby injuring investors.

That same day, after market hours, Erasca reported preliminary Phase 1 clinical data from ERAS-0015, revealing that a patient had died approximately one month after starting ERAS-0015.

On this news, Erasca’s stock price fell $9.25, or 48.3%, to close at $9.90 per share on April 28, 2026, thereby injuring investors further.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) ERAS-0015’s preclinical data was based on improper comparisons to RevMed and placed Erasca at risk of violating patent and trade secret protections; and (2) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Submit Your Information